APTINYX INC. overview

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has re-activated study sites and recommenced patient recruitment in a Phase 2 study of NYX-2925 in patients with fibromyalgia. Enrollment in the study had been suspended in March 2020 due to the escalation of the COVID-19 pandemic in the United States. “We are very pleased to be restarting this study,”...

EVANSTON, Ill., June 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment in its ongoing Phase 2 exploratory study of NYX-783 to evaluate the safety and efficacy of NYX-783 in patients with post-traumatic stress disorder (PTSD). The company anticipates reporting data from the study in late 2020. “The completion...

EVANSTON, Ill., June 16, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following upcoming investor conferences: 2020 BMO Prescription for Success Healthcare Conference on Tuesday, June 23, 2020 at 2:30 p.m. ET and; SVB Leerink CybeRx Series: 2 nd Annual CNS Forum on Wednesday June 24, 2020...

Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations into 2022 Conference call today at 5:00 p.m. EDT EVANSTON, Ill., May 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for...

EVANSTON, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 14, 2020 at 5:00 p.m. ET to report first quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please dial 1-866-930-5579 (domestic) or...

Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common stock offering provides runway into 2022 Conference call today at 5:00 p.m. EDT EVANSTON, Ill., March 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today...

EVANSTON, Ill., March 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Monday, March 30, 2020 at 5:00 p.m. ET to report fourth quarter and full year 2019 financial results and discuss recent business highlights. To access the live conference call, please dial 1-866-930-5579...

EVANSTON, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following investor conferences: 9 th Annual SVB Leerink Global Healthcare Conference at 9:30 a.m. EST on Thursday, February 27, 2020 in New York, NY; and Cowen 40 th Annual Health Care Conference at 12:00 p.m. EST on...